Matinas BioPharma Holdings, Inc. announced complete clinical resolution of a patient?s recurrent hemorrhagic cystitis due to Candida krusei (C. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203, Matinas? oral formulation of the potent antifungal amphotericin B. This patient was treated under Matinas? Expanded Access/Compassionate Use Program by Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.

A total of 11 patients with no other treatment options are currently receiving or have completed treatment with MAT2203 under this program, and several additional cases are under consideration. In each instance, the patient was not responding to or was resistant to azole therapy or was unable to receive azole therapy due to drug/drug interactions. All patients who experienced serious renal toxicity while receiving IV-amphotericin B who were subsequently treated with MAT2203 saw their renal toxicity reversed and renal function return to normal.

MAT2203 is not yet licensed or approved anywhere globally.